NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 26 June 2017 (#22)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a ***selection*** *of pre-screened, currently open health funding opportunities for which* ***South African institutions are eligible to apply****. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

Please be advised that you ***must contact the Research Grants Management Office (RGMO) Pre-Awards*** *(Dr Christa de Vries cdevries@sun.ac.za)* ***to inform of your intent to apply.***

Timelines:

Confirm your intent to apply as soon as possible, but not later than 30 days before the submission date.

All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.

The application will be submitted four (4) workdays before the application due date.

Important Notices

- **Why, When, and How You May Withdraw an Application** There are several reasons why an applicant chooses to withdraw an application: he or she spots a major error in the submitted application; there are new scientific developments that could significantly alter the application's competitiveness; or the application duplicates or has significant scientific overlap with another submission still under review.
- **Fogarty fact sheets** detail accomplishments and impact of NIH-supported global health research
- **Get Funding To Evaluate HIV Drug Resistance and Treatment Success** New studies are needed to research correlations between HIV drug resistance genotype, *in vitro* phenotype of the virus, and virologic outcome, as well as how to practically apply this knowledge.
- **Exploratory/Developmental FOA Focuses on Silencing HIV-1 Proviruses** HIV researchers, you may be interested in a reissued R01 funding opportunity announcement if you can do the following: propose a high-risk study aimed at understanding how to exploit an epigenetic regulatory pathway to develop novel small molecule or RNA therapeutics that can be useful for HIV-1 functional cure
- **New RFP for Evaluation and Testing Services for Vaccines and Other Biologics** A new request for proposals seeks services to provide a suite of preclinical, nonclinical, and clinical testing services for vaccine candidates, vaccine components (such as adjuvants), and biological product candidates that target infectious agents other than HIV
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Studies of Target Identification, Biomarkers and Disease Mechanisms Specific to Small Blood and Lymphatic Vessels in the CNS and Retina) (R01) **(NOT-NS-17-031)**

1. Cellular and Molecular Biology of Complex Brain Disorders

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-309) (PAR-17-310) **Type:** ***R01*** ***R21***

Application Due Date: July 31, 2017 then Standard dates Apply by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.

Budget: **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. **R21:** The total project period may not exceed 2 years.

2. Global Brain and Nervous System Disorders Research Across the Lifespan

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-314) **Type:** ***R01***
(PAR-17-313) ***R21***

Application Due Date: November 7, 2017; November 7, 2018; November 7, 2019. Apply by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in ***upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner***. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. These grants are expected to foster the development of more comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

Budget: **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants may request a project period of up to five years **R21:** Application budgets are limited to $125,000 per year in direct costs, but must reflect the actual needs of the proposed project. The project period may be up to 2 years.

3. HIV/HCV Co-Infections in Substance Abusers

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAS-17-311) **Type:** ***R01***

Application Due Date: September 7 2017 and January 7, 2018. Apply by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html and the HHS National Viral Hepatitis Action Plan 2017-2020: https://www.hhs.gov/hepatitis/blog/2017/01/19/updated-national-viral-hepatitis-action-plan-2017-2020.html

Budget: NIH intends to fund an estimate of 3-5 awards from this FOA and its reissuance, corresponding to a total of $3 million for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Multidisciplinary Studies of HIV/AIDS and Aging

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-321) **Type:** ***R01***
(PAR-17-320) ***R21***

Application Due Date: Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

Budget: **R01:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: cdevries@sun.ac.za